# The Use of Icosapent Ethyl on Vascular Progenitor Cells in Individuals With Elevated Cardiovascular Risk

> **NCT04562467** · PHASE4 · COMPLETED · sponsor: **Canadian Medical and Surgical Knowledge Translation Research Group** · enrollment: 70 (actual)

## Conditions studied

- Cardiovascular Diseases
- Cardiovascular Risk Factor
- Triglycerides High
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Icosapent Ethyl 1000 MG Oral Capsule [Vascepa]

## Key facts

- **NCT ID:** NCT04562467
- **Lead sponsor:** Canadian Medical and Surgical Knowledge Translation Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-24
- **Primary completion:** 2023-05-25
- **Final completion:** 2023-05-25
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2024-04-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04562467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04562467, "The Use of Icosapent Ethyl on Vascular Progenitor Cells in Individuals With Elevated Cardiovascular Risk". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04562467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*